Clinical trials: GI Disorders
Pancreatic Cancer, Metastatic Breast Cancer
Evaluation of the NantHealth GPS Cancer Test in Patients With Advanced Cancers
Among patients with advanced (metastatic) cancers, detailed characterizations of the tumor utilizing genomic and proteonomic techniques may help guide treatment.
- Conditions
- Pancreatic Cancer, Metastatic Breast Cancer, Metastatic Lung Cancer, Metastatic Colon Cancer
- Trial name
- NCT03073473
- Testing
- NantHealth GPS Cancer Test
- Where
- 10 sites in United States
- Volunteers
- 40 people
- Sponsor
- Cota Inc.
Crohn's Disease
Multiple Ascending Doses of AMG 139 in Healthy and Crohn's Disease Subjects
The purpose of this study is to assess the safety and tolerability of AMG 139 following multiple intravenous (IV) or subcutaneous (SC) dose administration in healthy subjects and in subjects with mild to severe Crohn's disease…
- Trial name
- NCT01258205
- Testing
- AMG 139
- Where
- 7 sites in United States, Australia
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Ulcerative Colitis
Efficacy and Safety Study of ABX464 as Maintenance Therapy in Patients With Moderate to Severe Ulcerative Colitis
A phase 2b study to evaluate the long-term efficacy and safety study of ABX464 50mg as maintenance therapy in patients with moderate to severe Ulcerative Colitis.
- Trial name
- NCT04023396
- Testing
- ABX464
- Where
- 120 sites in Austria, Belarus and 14 more
- Volunteers
- 217 people
- Sponsor
- Abivax S.A.
Irritable Bowel Syndrome With Diarrhea
Ibodutant for Relief of Irritable Bowel Syndrome With Diarrhoea (IBS-D)
Irritable Bowel Syndrome with diarrhoea (IBS-D) is a functional gastrointestinal disorder characterised by chronic or recurrent abdominal pain or discomfort and diarrhoea.
- Trial name
- IRIS-2 (NCT01303224)
- Testing
- Ibodutant
- Where
- 71 sites in Bulgaria, Czechia and 6 more
- Volunteers
- 565 people
- Sponsor
- Menarini Group
Solid Tumors
A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors
Researchers are looking for a better way to treat people with solid tumors. Before a treatment can be approved for people to take, researchers do clinical trials to better understand its safety and how it works.
- Trial name
- NCT04704154
- Testing
- Regorafenib, (Stivarga, BAY73-4506), Nivolumab (Opdivo)
- Where
- 34 sites in United States, Belgium and 6 more
- Volunteers
- 175 people
- Sponsor
- Bayer
Colorectal Cancer
Stool Sample Collection Study
The primary objective of this study is to obtain de-identified stool specimens from participants with colonoscopic biopsy-based histopathologic diagnosis of colorectal cancer (CRC) and/or a ≥1 cm colorectal polyp/adenoma/mass…
- Trial name
- NCT06294873
- Testing
- A screening device for the detection of colorectal and other aerodigestive tract cancers
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Innovis LLC
Solid Tumor of Epithelial Origin, Gastric Cancer
An A/B Dose Escalation Study of AbGn-7 Alone and With FOLFOX7 Treatment in Patients With Advanced Solid Tumors
The purpose of this study is to determine the safety and tolerability profile including the dose limiting toxicity of AbGn-7 in patients with chemo-refractory advanced solid tumor of epithelial origin, and of AbGn-7 in…
- Trial name
- NCT01466569
- Testing
- AbGn-7
- Where
- 4 sites in United States, Taiwan
- Volunteers
- 13 people
- Sponsor
- AbGenomics B.V Taiwan Branch
Adenoid Cystic Carcinoma, Colorectal Cancer
Study of Safety and Efficacy of RGT-61159 in Adults With Relapsed/Refractory Adenoid Cystic Carcinoma (ACC) or Colorectal Carcinoma (CRC)
Phase 1 study to evaluate safety, tolerability and anti-tumor activity of RGT-61159 in patients with ACC or CRC
- Trial name
- NCT06462183
- Testing
- RGT-61159, lenvatinib
- Where
- 9 sites in United States, Canada
- Volunteers
- 105 people
- Sponsor
- Rgenta Therapeutics Inc
Metastatic Colorectal Cancer
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
This open-label, exploratory study is designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or combinations, in participants with metastatic colorectal cancer (mCRC) whose tumors are…
- Trial name
- NCT04929223
- Testing
- Inavolisib, Bevacizumab, Cetuximab
- Where
- 84 sites in United States, Australia and 9 more
- Volunteers
- 542 people
- Sponsor
- Hoffmann-La Roche
Heartburn, Acid-dependent Diseases of the Gastrointestinal Tract
Comparative Pharmacodynamics and Pharmacodynamics Equivalence of Antareit 800 mg/10 ml Oral Suspension and Riopan 800 mg Chewable Tablets in Healthy Volunteers
Comparative study of the pharmacodynamic parameters and pharmacodynamic equivalence (bioequivalence) of drug Antareit 800 mg/10 ml oral suspension and drug Riopan 800 mg chewable tablets in healthy volunteers.
- Conditions
- Heartburn, Acid-dependent Diseases of the Gastrointestinal Tract, Symptomatic Treatment of Gastric and Duodenal Ulcers
- Trial name
- NCT06098742
- Testing
- Antareit
- Where
- 2 sites in Russia
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Valenta Pharm JSC
Gastroesophageal Reflux Disease (GERD)
Assessment of the Role of Tegaserod Therapy in the Management of Gastroesophageal Reflux Disease (GERD) Symptoms in Patients With Incomplete Response to Proton Pump Inhibitors (PPIs).
Study to assess the effects of tegaserod added to PPI therapy in the resolution of heartburn and regurgitation in patients with incomplete relief from PPIs .
- Trial name
- NCT00171483
- Testing
- Tegaserod
- Where
- 7 sites in United States
- Volunteers
- 30 people
- Sponsor
- Novartis
Gastroesophageal Reflux Disease
Ilaprazole for the Treatment of Gastroesophageal Reflux Disease (GERD) in Chinese Patients
This study is designed to evaluate the efficacy and tolerability of ilaprazole relative to that of esomeprazole in healing erosive esophagitis and resolving accompanying symptoms of GERD.
- Trial name
- NCT02860624
- Testing
- 10 mg ilaprazole, 40mg esomeprazole
- Volunteers
- 550 people
- Sponsor
- Livzon Pharmaceutical Group Inc.
Crohn Disease, Colitis, Ulcerative
A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease
The primary objective of the study is to evaluate the efficacy of 2 different maintenance dose regimens of TEV-48574 subcutaneous (sc) administered every 4 weeks (Q4W) in adult participants with inflammatory bowel disease (IBD).
- Trial name
- NCT05668013
- Testing
- TEV-48574 Dose Regimen A, TEV-48574 Dose Regiment B
- Where
- 93 sites in United States, Austria and 14 more
- Volunteers
- 247 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D LLC
Ulcerative Colitis (UC)
The Purpose of This Study is to Evaluate the Efficacy and Safety of 627 in the Treatment of UC
This study will evaluate the efficacy and safety of 627 in patients with UC.
- Trial name
- NCT07507513
- Testing
- 627
- Where
- China
- Volunteers
- 288 people
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Head and Neck Squamous Cell Carcinoma HNSCC, Non-Small Cell Lung Cancer NSCLC
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
This is a study to evaluate the safety and preliminary anti-tumor activity of STRO-004 in adults with metastatic cancer. This study includes 3 parts: Part 1A is a dose escalation study of STRO-004 monotherapy in selected tumor…
- Conditions
- Head and Neck Squamous Cell Carcinoma HNSCC, Non-Small Cell Lung Cancer NSCLC, Esophageal Cancer, Gastric Cancer
- Trial name
- NCT07227168
- Testing
- STRO-004, Pembrolizumab
- Where
- 9 sites in United States
- Volunteers
- 200 people
- Sponsor
- Sutro Biopharma, Inc.
Pharmacokinetics of Zolbetuximab, Gastric Cancer
A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer
Zolbetuximab is being studied as a treatment for people with cancer in and around the stomach or cancer where the food pipe (esophagus) joins the stomach (gastroesophageal junction cancer).
- Conditions
- Pharmacokinetics of Zolbetuximab, Gastric Cancer, Gastro-esophageal Junction (GEJ) Cancer, Pharmacokinetics of Oxaliplatin
- Trial name
- ILUSTRO (NCT03505320)
- Testing
- zolbetuximab, oxaliplatin, leucovorin
- Where
- 21 sites in United States, France and 4 more
- Volunteers
- 143 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Squamous Cell Carcinoma of the Head and Neck, Melanoma
SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas
This is a Phase 1 first in human, open label, multi-center, dose escalation and dose expansion study to evaluate the safety, tolerability, PK, anti-tumor activity and pharmacodynamic effects of SL-279252 in subjects with advanced…
- Conditions
- Squamous Cell Carcinoma of the Head and Neck, Melanoma, Non Small Cell Lung Cancer, Urothelial Carcinoma
- Trial name
- NCT03894618
- Testing
- SL-279252
- Where
- 5 sites in United States, Belgium and 2 more
- Volunteers
- 49 people
- Sponsor
- Shattuck Labs, Inc.
Metastatic Colorectal Cancer
Geptanolimab(GB226) Combined With Fruquintinib in the Treatment of Metastatic Colorectal Cancer
This study is a multicenter, dose-escalating phase Ib clinical study to evaluate the safety and tolerability of GB226 in combination with fruquintinib in the treatment of mCRC, evaluate the pharmacokinetic characteristics of…
- Trial name
- NCT03977090
- Testing
- Geptanolimab Injection, Fruquintinib
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Genor Biopharma Co., Ltd.
Crohn's Disease
Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease
To provide open-label re-treatment with PROCHYMAL to participants enrolled in companion Protocol 603 to evaluate the safety in participants with active Crohn's disease who are resistant to standard Crohn's disease therapies.
- Trial name
- NCT01233960
- Testing
- Prochymal®
- Where
- 20 sites in United States, Australia and 1 more
- Volunteers
- 73 people
- Sponsor
- Mesoblast, Inc.
Short Bowel Syndrome
A Study of Teduglutide in Japanese People With Short Bowel Syndrome
The main aims of this study are to check for side effects from treatment with teduglutide (Revestive) and how well teduglutide controls symptoms of short bowel syndrome.
- Trial name
- NCT05023382
- Testing
- Teduglutide
- Where
- Japan
- Volunteers
- 250 people
- Sponsor
- Takeda
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.